title: [Perspective of personalized (precise) cancer therapy based on predictive biomarkers].
abstract: The epidermal growth factor receptor (EGFR), a receptor tyrosine kinase, triggers a downstream signaling cascade through areas such as the RAS-RAF-MAPK, PI3K-AKT and JAK-STAT pathways, which are involved in cell proliferation, dedifferentiation and inhibition of apoptosis. Two anti-EGFR monoclonal antibodies, cetuximab and panitumumab, are currently available for the treatment of metastatic colorectal cancer. KRAS is a validated predictive biomarker for anti-EGFR therapy and tumor KRAS status should be determined whenever anti-EGFR therapy is considered in the treatment of metastatic colorectal cancer. On the other hand, the promising biomarkers such as NRAS, BRAF and PIK3CA for anti-EGFR monoclonal antibody, and pVEGF-A for bevacizumab have been reported. We review the biomarkers associated with personalized therapy in colorectal cancer.
authors.affiliation: Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East.
authors.forename: Shozo
authors.initials: S
authors.lastname: Osera
authors.affiliation: Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East.
authors.forename: Takayuki
authors.initials: T
authors.lastname: Yoshino
mesh_terms: D015415:Biomarkers / Q000032:analysis*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D006801:Humans; D057285:Precision Medicine
chemical_list: D015415:Biomarkers